<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03561935</url>
  </required_header>
  <id_info>
    <org_study_id>PVC study</org_study_id>
    <nct_id>NCT03561935</nct_id>
  </id_info>
  <brief_title>Beta-blocker vs. Ic Antiarrhythmic Drug for PVC</brief_title>
  <official_title>Outcome of Medical Treatment for Idiopathic Premature Ventricular Complexes - Beta-blocker vs Ic Antiarrhythmic Agent; Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yong Seog Oh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard medical therapy of idiopathic premature ventricular complex consists of beta
      blocker and Ic antiarrhythmic agent. However, the difference in the efficacy of two drugs has
      not been well investigated. This prospective randomized study aimed to compare the efficacy
      of beta-blocker and Ic antiarrhythmic agent in the treatment of symptomatic patients with
      idiopathic premature ventricular complex.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A premature ventricular complex is frequently observed in routine clinical practice and
      patients without structural heart disease occasionally have benign outcomes. The initial
      therapy of symptomatic premature ventricular complex is medical treatment with beta-blocker,
      calcium channel blocker or antiarrhythmic agents. However, no large prospective study has
      been performed to identify the difference in the efficacy between drugs. The current study
      was designed to compare the efficacy between beta-blocker and class Ic antiarrhythmic agent.
      Patient with symptomatic PVC more than 6000 episode per 24 hours is included. Exclusion
      criteria are evidence of structural heart disease, coronary heart disease, significant
      bradycardia or use of a concomitant antiarrhythmic agent. Patients are randomized into
      beta-blocker group (propranolol) and Ic antiarrhythmic agent group (propafenone). Response to
      the drug is evaluated after 2 months from randomization by 24 hours Holter and questionnaire.
      The primary endpoint is more than 80% PVC reduction or PVC burden less than 300 beats per 24
      hours. The secondary endpoint is patient's symptom evaluated by questionnaire and the number
      of PVCs measured in 24 hours Holter.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">November 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in PVC frequency on 24hrs holter</measure>
    <time_frame>two months after randomization</time_frame>
    <description>PVC reduction of &gt;80% or &lt;300 beats/day</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Premature Ventricular Complex</condition>
  <arm_group>
    <arm_group_label>Propafenone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prescribtion of propafenone for the management of premature ventricular complex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indenol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prescribtion of indenol for the management of premature ventricular complex</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propafenone</intervention_name>
    <description>prescribing propafenone for the management of premature ventricular complex</description>
    <arm_group_label>Propafenone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indenol</intervention_name>
    <description>prescribing indenol for the management of premature ventricular complex</description>
    <arm_group_label>Indenol group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  over 19 years old &gt;6000 PVCs/24hrs

        Exclusion Criteria:

          -  Left ventricular ejection fraction &lt;50% or Significant valvular disease (â‰¥moderate)
             History of coronary artery disease Use of a concomitant antiarrhythmic agent
             Significant bradycardia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong-Seog Oh, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong-Seog Oh, MD,PhD</last_name>
    <phone>82-2-2258-6035</phone>
    <email>oys@catholic.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ju Youn Kim, MD</last_name>
    <phone>82-10-5482-7307</phone>
    <email>zzoo921@catholic.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul St Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seo Ch-gu</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ju Youn Kim, MD</last_name>
      <phone>82-10-5482-7307</phone>
      <email>zzoo921@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Yong Seog Oh, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>June 19, 2018</last_update_submitted>
  <last_update_submitted_qc>June 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Yong Seog Oh</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propafenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

